Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FBP1 | P09467 | 2/20 | 0.40 |
| ▸ | ATM | Q13315 | 1/20 | 0.38 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.38 |
| ▸ | AR | P10275 | 4/20 | 0.37 |
| ▸ | MAPT | P10636 | 2/20 | 0.37 |
| ▸ | HTT | P42858 | 1/20 | 0.35 |
| ▸ | POLB | P06746 | 1/20 | 0.35 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.35 |
| ▸ | NR3C2 | P08235 | 1/20 | 0.34 |
| ▸ | THRB | P10828 | 1/20 | 0.34 |
| ▸ | RORC | P51449 | 1/20 | 0.34 |
| ▸ | PGR | P06401 | 1/20 | 0.34 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5644117 | 0.92 | FBP1 (0.43) | FBP1ARMAPTPOLBNPSR1 | |
| SCHEMBL5643422 | 0.92 | POLB (0.40) | FBP1ATMTDP1MAPTPOLB | |
| SCHEMBL3538023 | 0.80 | POLB (0.45) | ARPOLBNPSR1NR3C2PGR | |
| SCHEMBL5644090 | 0.79 | ATM (0.40) | ATMTDP1ARMAPTHTT | |
| SCHEMBL5645183 | 0.79 | AR (0.43) | ATMTDP1ARHTTNR3C2 | |
| SCHEMBL14340596 | 0.78 | NR3C1 (0.52) | POLBNPSR1NR3C2PGRCYP3A4 | |
| SCHEMBL142930 | 0.77 | THRB (0.44) | FBP1ATMTDP1MAPTHTT | |
| SCHEMBL3954561 | 0.77 | NR3C1 (0.50) | ARPOLBNPSR1NR3C2PGR | |
| SCHEMBL5642117 | 0.75 | POLB (0.48) | FBP1MAPTHTTPOLBNPSR1 | |
| SCHEMBL14035563 | 0.75 | THRB (0.44) | FBP1ATMTDP1MAPTHTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7129270-B2 | Nonsteroidal antiinflammatory agents | Schėring AG (DE) | 2006-10-31 | — | — | US | disclosed |
| US-20060040933-A1 | Nonsteroidal antiinflammatory agents | JAROCH STEFAN | 2006-02-23 | — | — | US | disclosed |
| US-20040254249-A1 | Nonsteroidal antiinflammatory agents | JAROCH STEFAN (DE) | 2004-12-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060040933-A1 | Nonsteroidal antiinflammatory agents | PTGES, PTGES2, PTGS1 | FBP1 2105/4885ATM 4456/4885TDP1 2586/4885 |
| US-20040254249-A1 | Nonsteroidal antiinflammatory agents | PTGS1, PTGER1, PTGES2 | FBP1 477/4885ATM 4710/4885TDP1 2277/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.